Peptide News Digest

Camurus Oclaiz Second Manufacturing CRL, MBX Canvuparatide Phase 2 + 1-Year OLE Hit, AJMC GLP-1 Emerging Indications, Parabilis $670M IPO Debut, The Hill on MAHA Peptide Push

Camurus second CRL on Oclaiz, MBX canvuparatide Phase 2 + 1-yr data set up Q3 Phase 3, Parabilis breaks IPO record at $670M, AJMC quantifies GLP-1 indication creep.

5 stories · Covering regulatory, clinical-trials, research, industry

Editor's Note

The Camurus Oclaiz story sharpened today. The June 10 PDUFA produced a Complete Response Letter, the second the program has received, and both are rooted in the same September 2024 cGMP inspection at a third-party manufacturer. Neither CRL touched clinical efficacy or safety. Camurus says it can resubmit in Q4 2026 with a second validated manufacturer, which would push potential approval to the first half of 2027. Yesterday's digest framed the decision as 'pending' because the public CRL announcement landed on June 10 and the search tooling did not surface it until today. Beyond Oclaiz, MBX Biosciences released full Phase 2 Avail data for once-weekly canvuparatide in chronic hypoparathyroidism, with a 63% responder rate at 12 weeks and durability through one year, setting up a registrational Phase 3 in Q3 2026. Parabilis Medicines closed its Nasdaq debut at $31.60, a 58% first-day gain on an upsized $670 million raise that breaks the venture-backed biotech IPO record. AJMC put numbers on the GLP-1 indication creep, and The Hill ran a Washington-policy framing of the July PCAC meeting that captures how MAHA pressure now intersects with the regulatory calendar.

Regulatory

Camurus Discloses Second Complete Response Letter for Oclaiz, Both Tied to the Same Manufacturer Inspection

Camurus said on June 10 that the FDA had issued a Complete Response Letter on the Oclaiz (CAM2029) NDA, the second the program has received and the second based solely on unresolved observations from a September 2024 cGMP inspection at a third-party contract manufacturer. The CRL did not cite clinical efficacy or safety. Camurus expects to resubmit in Q4 2026 with a second validated manufacturer; an approval pushed to the first half of 2027 leaves the US launch about a year behind the EU and UK rollouts (under the Oczyesa brand) that landed in 2025.

#camurus #oclaiz #cam2029 #octreotide #acromegaly #complete-response-letter #manufacturing
Clinical Trials

MBX Biosciences Canvuparatide Hits 63% Responder Rate in Phase 2 Avail, Sustains Through One-Year Open-Label Extension, Phase 3 Set for Q3 2026

MBX Biosciences (Nasdaq: MBX) on June 12 reported full 12-week Phase 2 Avail data and one-year open-label extension results for once-weekly canvuparatide, a precision PTH peptide for chronic hypoparathyroidism. The trial hit its primary endpoint with a 63% responder rate versus 31% on placebo at 12 weeks; the OLE delivered a 79% responder rate at six months and 57% at one year. Patients showed normalized serum calcium, reduced urine calcium excretion, restored bone metabolism, and improved eGFR; 90% of OLE patients remained on study at one year with no new safety signals. A registrational Phase 3 in chronic hypoparathyroidism starts Q3 2026.

#mbx-biosciences #canvuparatide #hypoparathyroidism #pth-peptide #avail-trial #phase-2 #open-label-extension
Research

AJMC: 51.3% of GLP-1 Users Now Carry an Emerging-Indication Diagnosis, OSA Leading at 25.5%

AJMC reported real-world claims data showing that 51.3% of patients on GLP-1 drugs carry at least one diagnosis tied to an emerging GLP-1 indication, 13.8% carry two, and 6.8% carry three or more. Obstructive sleep apnea led the comorbidity prevalence at 25.5%, followed by major depressive disorder at 18.2%, chronic kidney disease at 10.6%, and NAFLD/NASH at 10.3%. The numbers quantify the indication creep the field has been narrating since ADA: prescribers are increasingly writing GLP-1s for patients whose secondary conditions align with the expanding regulatory map (Wegovy CV, FLOW kidney, SURMOUNT-OSA, ESSENCE MASH).

#glp-1 #real-world-evidence #indication-expansion #obstructive-sleep-apnea #chronic-kidney-disease #ajmc
Industry

Parabilis Medicines Closes IPO Debut Up 58% on Upsized $670M Raise, Setting Venture-Backed Biotech Record

Parabilis Medicines (Nasdaq: PBLS) opened June 10 at $33.35 and closed at $31.60 on its Nasdaq debut, a 58% first-day gain after pricing an upsized $670 million IPO at $20 per share — above the previously announced $17-19 range and well past the $476 million initial target Parabilis set on June 4. The 33.5 million-share offering breaks the venture-backed biotech IPO record. Proceeds extend runway for the lead asset zolucatetide, a cell-penetrating helical peptide targeting Wnt/β-catenin in cancer, with a Phase 3 in desmoid tumors expected in the first half of 2027.

#parabilis-medicines #zolucatetide #helical-peptide #ipo #desmoid-tumors #wnt-beta-catenin #biotech-ipo-record
Regulatory

The Hill: FDA to Weigh Lifting Restrictions on MAHA-Favored Peptides at July 23-24 PCAC

The Hill ran a Washington-policy framing of the July 23-24 PCAC peptide-compounding meeting, casting the agenda as the regulatory follow-through on HHS Secretary Robert F. Kennedy Jr.'s repeated pledges to ease access to wound-healing, weight-loss, and longevity peptides favored by the Make America Healthy Again movement. The committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. Written comment closes July 9; oral-presentation requests close June 30, eighteen days from today.

#fda #pcac #maha #rfk-jr #bpc-157 #compounding #peptide-policy